Biogen Inc.’s controversial Alzheimer’s drug Aduhelm produced brain swelling in 35% of patients who took the approved dose, although most didn’t experience symptoms, company researchers said in a study.
The study in JAMA Neurology found that 362 of 1,029 patients who received the approved dose of the drug experienced the side effect, which showed up in brain imaging of people in two big clinical trials of the drug. While most cases weren’t accompanied by symptoms, 94 patients experienced headache, confusion, dizziness or other effects.
Researchers are trying to understand the potential implications of the side effects—called…
